Amarin Corporation
Amarin Corporation
Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company is best known for its prescription drug, Vascepa, which is derived from fish oil and is used to reduce cardiovascular risk.
History[edit]
Amarin Corporation was founded in 1993 and is headquartered in Dublin, Ireland. Initially, the company focused on the development of lipid science and the treatment of cardiovascular disease. Over the years, Amarin has shifted its focus to the commercialization of its flagship product, Vascepa.
Products[edit]
Vascepa[edit]
Vascepa is Amarin's primary product, an omega-3 fatty acid-based drug designed to lower triglyceride levels in patients with severe hypertriglyceridemia. It has been approved by the Food and Drug Administration (FDA) for use in the United States and has undergone various clinical trials to expand its indications.
Research and Development[edit]
Amarin Corporation invests heavily in research and development to explore new therapeutic uses for Vascepa and other potential products. The company conducts clinical trials to assess the efficacy and safety of its products in reducing cardiovascular events.
Market and Sales[edit]
Amarin markets Vascepa primarily in the United States, with efforts to expand its presence in international markets. The company employs a direct sales force and partners with other pharmaceutical companies to promote its products.
Legal and Regulatory Affairs[edit]
Amarin has been involved in various legal and regulatory matters, including patent disputes and challenges related to the marketing and labeling of Vascepa. The company actively engages with regulatory bodies to ensure compliance and to seek approval for expanded indications of its products.
Corporate Structure[edit]
Amarin Corporation is publicly traded on the NASDAQ stock exchange under the ticker symbol AMRN. The company is governed by a board of directors and managed by an executive team responsible for strategic decisions and day-to-day operations.
Related pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian